Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)
Executive Summary
Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay
You may also be interested in...
Pfizer Norvasc Patent: Will Court Limit Extension To “Approved” Product?
Dr. Reddy's reliance on Norvasc data in its 505(b)(2) application for amlodipine maleate could impact an appeals court's determination of whether Pfizer's patent term extension applies only to the approved besylate salt form of the drug
Pfizer Norvasc Patent: Will Court Limit Extension To “Approved” Product?
Dr. Reddy's reliance on Norvasc data in its 505(b)(2) application for amlodipine maleate could impact an appeals court's determination of whether Pfizer's patent term extension applies only to the approved besylate salt form of the drug
PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
FDA should specify that ANDAs which change certification from Paragraph III to Paragraph IV should trigger for a 30-month stay, the Pharmaceutical Research & Manufacturers of America states in comments on FDA's proposed rule